Vaccine – BIL06v

Biosceptre is developing a vaccine program which recruits the individual’s immune system to specifically target cancer cells that express nfP2X7.

Biosceptres’ second pipeline product BIL06v – uses a precise peptide sequence conjugated to a protein to stimulate the immune system to generate antibodies that bind to nfP2X7.

BIL06v has been shown to reduce tumour growth in vivo in mice and Biosceptre data indicates safety and efficacy in human as well. A Phase 1 trial is planned for 2017.